About
Research grants and fellowships, MyeTRIAL Partnership, Clinical Service Excellence Programme, Peer Buddy service, Myeloma Helpline (260+ languages), Knowledge is Power awareness campaign, drug appraisal advocacy, Precursor Framework
Key Metrics
Multiple NHS drug approvals secured in 2025 including world-first BVD approval, benefitting thousands of myeloma patients
Key Metric 1
Key Outcomes
- IsaVRD quadruplet treatment approved in England, Wales and Scotland — 63% of patients still in remission after five years in trials
Geography
UK-Wide